Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic
Lugano (Switzerland) and Rome (Italy)– May 27, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Angelini Pharma (“Angelini”), an international pharmaceutical company, part of the Italian privately-owned multi-business Angelini Industries, that researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health, announce today the signing of the Distribution and Licence Agreement renewal in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic for AULIN® and MESULID® (Nimesulide) for the treatment of acute (short-term) pain.
Erik Lommerde, Executive VP International Operations at Angelini Pharma, remarked: “We are delighted to renew our partnership with Helsinn. This collaboration is built on a foundation of mutual trust, highlighted by our shared commitment to professional excellence, in-depth product knowledge, and high-quality service. This alliance is crucial for both parties and represents a strong business relationship.”
Dr. Melanie Rolli, Helsinn Group CEO, commented: “We are pleased to have signed this agreement with Angelini and honored to maintain our ongoing collaboration. Our long-standing partnership with Angelini exemplifies how Helsinn fosters relationships and alliances to deliver essential products to patients. We appreciate their extensive reach in these countries, which enables patient access to this much needed treatment.”
Discover more from Life News Agency
Subscribe to get the latest posts to your email.
